Neurocrine Biosciences, Inc.

NBIX • Biotechnology

$155.64

▼ -2.71 (-1.71%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$16.22B

Crecimiento

11.4%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 16.7%Crecimiento positivo de ingresos · 24.5%Flujo de caja libre positivo · 7.52Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.13

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$155.64

Change-1.71%

Shares Out104.20M

Market Cap$16.22B

Enterprise Value$16.23B

52W Range122.14 - 186.12

Beta0.39

P/E22.99

P/S4.81

P/B4.06

P/FCF18.63

EV/Sales4.81

Price$155.64

Change-1.71%

Shares Out104.20M

Market Cap$16.22B

Enterprise Value$16.23B

52W Range122.14 - 186.12

Beta0.39

P/E22.99

P/S4.81

P/B4.06

P/FCF18.63

EV/Sales4.81

EV/EBITDA18.45

EV/FCF18.65

Earnings Yield4.35%

FCF Yield5.37%

Dividend Yield0.00%

Gross Margin98.18%

Oper. Margin21.64%

Profit Margin16.73%

Debt/Eq0.13

Current Ratio3.39

Quick Ratio3.30

Revenue 5Y11.36%

FCF 5Y11.87%

Target$203.11

Target Upside30.50%

Target Median$206.00

Target Range165.00 - 230.00

Volume2.17M

Avg Volume1.21M

EPS Surprise0.72

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

86/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

57/100

Por qué este puntaje▼

Márgenes estables o en mejora · 16.7%Crecimiento positivo de ingresos · 24.5%Flujo de caja libre positivo · 7.52Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.13Liquidez saludable · 3.39

Analyst view

Analyst sentiment and price target

NBIX

Analyst sentiment

Based on 37 analyst votes · 2026-09-05

93/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-31

Bajo

$160.00

Promedio

$197.25

Mediana

$197.50

Alto

$230.00

Resumen de la compañía

IPO: 5/23/1996

Industria: Biotechnology

P/B i: 4.06

Deuda / Patrimonio i: 0.13

Margen operativo: 21.64%

Margen neto: 16.73%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.13

Ratio corriente: 3.39

Ratio rápido: 3.30

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Norwalk Leslie V

Transacción: 07/29/2026

VENTA

Cambio

-842

Precio

$139.43

Presentación

07/30/2026

Tipo

VENTA

Norwalk Leslie V

Transacción: 07/29/2026

COMPRA

Cambio

+842

Precio

$139.43

Presentación

07/30/2026

Tipo

COMPRA

Norwalk Leslie V

Transacción: 07/28/2026

VENTA

Cambio

-1,250

Precio

$182.01

Presentación

07/30/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Norwalk Leslie V	VENTA	-842	$139.43	07/29/2026	07/30/2026
Norwalk Leslie V	COMPRA	+842	$139.43	07/29/2026	07/30/2026
Norwalk Leslie V	VENTA	-1,250	$182.01	07/28/2026	07/30/2026
Delaet Ingrid	VENTA	-4,367	$106.02	07/10/2026	07/13/2026
Delaet Ingrid	VENTA	-4,367	$181.02	07/10/2026	07/13/2026
Lippoldt Darin	VENTA	-10,000	$81.49	07/09/2026	07/13/2026
Lippoldt Darin	VENTA	-10,000	$179.60	07/09/2026	07/13/2026
Delaet Ingrid	VENTA	-8,433	$103.52	07/09/2026	07/09/2026
Delaet Ingrid	VENTA	-8,433	$178.72	07/09/2026	07/09/2026
Delaet Ingrid	VENTA	-2,737	$103.52	07/08/2026	07/09/2026
Delaet Ingrid	VENTA	-2,737	$178.54	07/08/2026	07/09/2026
Delaet Ingrid	VENTA	-3,401	$103.52	07/07/2026	07/09/2026
Delaet Ingrid	VENTA	-3,401	$178.57	07/07/2026	07/09/2026
Lippoldt Darin	VENTA	-1,690	$81.49	06/29/2026	06/30/2026
Lippoldt Darin	VENTA	-1,690	$170.81	06/29/2026	06/30/2026
Lippoldt Darin	VENTA	-200	$81.49	06/26/2026	06/30/2026
Lippoldt Darin	VENTA	-200	$169.56	06/26/2026	06/30/2026
Onyia Jude	VENTA	-2,441	Not reported	06/05/2026	06/09/2026
SHERWIN STEPHEN A	VENTA	-10,000	$79.79	06/05/2026	06/09/2026
SHERWIN STEPHEN A	VENTA	-1,843	$167.31	06/05/2026	06/09/2026

Sobre la compañía

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.

Fuente - Link

Competidores

COO ELAN HOLX ICLR RDY SMMT SNN TEM UHS VTRS

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference.

PRNewsWire

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?

NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.

Zacks Investment Research

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.

Zacks Investment Research

B. Metzler seel. Sohn & Co. AG Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX

B. Metzler seel. Sohn and Co. AG acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,986 shares of the company's stock, valued at approximately $1,009,000. Other institutional investors and hedge

Defense World

Allworth Financial LP Invests $2.50 Million in Neurocrine Biosciences, Inc. $NBIX

Allworth Financial LP purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,853 shares of the company's stock, valued at approximately $2,503,000. A number of other hedge funds

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-05	1.22	1.94	0.72
2026-02-11	1.8	1.88	0.08
2025-10-28	1.58	2.04	0.46
2025-07-30	0.98	1.06	0.08
2025-05-05	0.535	0.08	-0.455
2025-02-06	1.62	1	-0.62
2024-10-30	1.51	1.24	-0.27
2024-08-01	1.05	0.63	-0.42
2024-05-01	1.01	0.42	-0.59
2024-02-07	1.15	1.44	0.29
2023-10-31	0.97	0.82	-0.15
2023-08-01	0.78	0.95	0.17